Financial Data and Key Metrics Changes - The company achieved a $250 million annual run rate cost savings target a quarter early, with cash and cash equivalents totaling $474 million and no bank debt, providing a margin of safety [5][6][78] - Total adjusted EBITDA improved to negative $28 million in 2025 from negative $99 million in 2024, representing a 72% improvement [12] - Cash burn decreased significantly from $110 million in 2024 to $38 million in 2025, attributed to restructuring efforts [13] Business Line Data and Key Metrics Changes - Cell engineering revenue reached $39 million in 2025, an 8% increase compared to 2024, with 120 revenue-generating programs, a 10% year-over-year increase [9] - Biosecurity revenue was $10 million in 2025, with a segment gross margin of 18% [10] - R&D expenses for cell engineering decreased by 63% from $84 million in 2024 to $31 million in 2025, while G&A expenses decreased by 57% from $33 million to $14 million [11] Market Data and Key Metrics Changes - The company reaffirmed its total revenue guidance for 2025, expecting between $167 million and $187 million, with cell engineering revenue projected between $117 million and $137 million, and biosecurity revenue expected to be at least $40 million [14] Company Strategy and Development Direction - The company is transitioning from an R&D solutions business to the life science tool space, focusing on automation and data points as key growth areas [4][16] - The strategic focus includes maintaining a cash margin of safety while exploring growth opportunities leading into 2026 [6][78] - The company aims to leverage its automation technology to address the demand for increased output from existing R&D resources, particularly in the context of economic pressures and competition [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of automation as a significant revenue driver, aiming to make it as general-purpose as the lab bench [81][83] - The company is exploring opportunities in the CRO services market, emphasizing the importance of automation to reduce R&D costs and improve scalability [62][64] - Management highlighted the potential for AI-enabled science and the need for investment in automated lab environments to enhance research capabilities [55][57] Other Important Information - The company launched its first reagent product, a cell-free protein synthesis kit, which has already garnered interest in the academic research market [69][75] - The company is actively engaging with customers to provide competitive pricing for CRO services, aiming to match overseas providers [96] Q&A Session Summary Question: Is Ginkgo Automation expected to become a primary driver of revenue? - Management indicated that automation is anticipated to be a significant part of future business, potentially becoming the majority of revenue if successful in making it as general as the lab bench [81][83] Question: Are there plans for acquisitions? - Currently, there are no immediate acquisition plans, but the company remains open to opportunities if they align well with strategic goals [84] Question: Can you elaborate on Ginkgo RNA solutions? - RNA solutions are being developed as a service based on expertise in RNA discovery, with the potential for more offerings in the future [86][88] Question: Can you provide more details on AdMe data generation software? - Management discussed the potential for developing AI models based on generated AdMe data, emphasizing the importance of providing competitive pricing for CRO services [91][97]

Financial Performance & Targets - Ginkgo achieved its target of $250 million in annualized run-rate cost savings from Q1 2024 to Q2 2025[13, 50] - Ginkgo's Q2 2025 Cell Engineering revenue was $39 million, an 8% increase year-over-year[34] - Biosecurity revenue for Q2 2025 was $10 million, a 48% decrease year-over-year[34] - The company reaffirms its total revenue guidance for FY2025, projecting $167-$187 million, including $117-137 million from Cell Engineering and $40+ million from Biosecurity[37, 52] - Ginkgo aims to reach Adjusted EBITDA breakeven by the end of 2026[11, 46, 53] - Ginkgo had $474 million in cash, cash equivalents, and marketable securities with no bank debt[15, 16] Strategic Initiatives - Ginkgo is expanding from its Solutions business into tools, launching its first direct-to-scientist product: a cell-free protein synthesis system[11, 43, 63] - Ginkgo's Automation and Datapoints are establishing themselves as critical tools in AI-enabled science[43, 143] - Ginkgo has sampled flights originating from 128 countries, representing 65% of nations globally[33]

[PART I. FINANCIAL INFORMATION](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section details Ginkgo's unaudited financial statements and management's discussion and analysis [Item 1. Financial Statements (Unaudited)](index=6&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents Ginkgo's unaudited consolidated financial statements and detailed notes for H1 2025 and 2024 [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets, liabilities, and stockholders' equity decreased from December 31, 2024, to June 30, 2025 | Metric | As of June 30, 2025 (in thousands) | As of December 31, 2024 (in thousands) | | :-------------------------- | :--------------------------------- | :----------------------------------- | | Total Assets | $1,231,009 | $1,377,449 | | Total Liabilities | $618,057 | $661,391 | | Total Stockholders' Equity | $612,952 | $716,058 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss significantly reduced in H1 2025 due to lower operating expenses, despite a Q2 revenue decrease Three Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change (YoY) | | :-------------------------- | :--------- | :----------- | :----------- | | Total Revenue | $49,604 | $56,206 | $(6,602) | | Net Loss | $(60,300) | $(217,181) | $156,881 | | Basic Net Loss Per Share | $(1.10) | $(4.23) | $3.13 | Six Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change (YoY) | | :-------------------------- | :--------- | :----------- | :----------- | | Total Revenue | $97,922 | $94,150 | $3,772 | | Net Loss | $(151,257) | $(383,092) | $231,835 | | Basic Net Loss Per Share | $(2.77) | $(7.55) | $4.78 | [Condensed Consolidated Statements of Stockholders' Equity](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) Stockholders' equity decreased to **$613.0 million** by June 30, 2025, primarily due to net loss Total Stockholders' Equity (in thousands) | Date | Amount | | :-------------------- | :------- | | June 30, 2025 | $612,952 | | December 31, 2024 | $716,058 | Stock-Based Compensation Expense (Six Months Ended June 30, in thousands) | Year | Amount | | :--- | :------- | | 2025 | $42,678 | | 2024 | $77,928 | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash, cash equivalents, and restricted cash decreased by **$354.4 million** due to investing activities Cash Flows (Six Months Ended June 30, in thousands) | Activity | 2025 | 2024 | | :------------------------------------------ | :--------- | :--------- | | Net cash used in operating activities | $(91,775) | $(173,649) | | Net cash used in investing activities | $(262,572) | $(38,951) | | Net cash used in financing activities | $(305) | $(1,071) | | Net decrease in cash, cash equivalents and restricted cash | $(354,392) | $(213,844) | - Purchases of marketable debt securities significantly increased cash used in investing activities in H1 2025 to **$320.1 million**, compared to none in H1 2024[23](index=23&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) These notes detail Ginkgo's business, accounting policies, acquisitions, restructuring, fair value, investments, revenue, and segment data [Note 1. Basis of Presentation and Summary of Significant Accounting Policies](index=12&type=section&id=Note%201.%20Basis%20of%20Presentation%20and%20Summary%20of%20Significant%20Accounting%20Policies) Ginkgo aims to engineer biology, offering R&D services and biosecurity, effected a 1:40 reverse stock split, and began investing in marketable debt securities - Ginkgo's mission is to make biology easier to engineer, providing biological R&D services through its Foundry (equipment, automation, software, data) and Codebase (biological assets, data)[27](index=27&type=chunk) - The Biosecurity business offers biomonitoring and bioinformatics support services (Canopy and Horizon) to identify, monitor, prevent, and mitigate biological threats for government and commercial customers[28](index=28&type=chunk) - A one-for-forty (1:40) reverse stock split for common stock was effected on **August 19, 2024**[30](index=30&type=chunk) - In 2025, the company began investing excess cash in marketable debt securities, classified as available-for-sale[35](index=35&type=chunk) [Note 2. Acquisitions](index=13&type=section&id=Note%202.%20Acquisitions) In 2024, Ginkgo acquired platform assets from AgBiome and Zymergen's IP, plus three other asset acquisitions expensed as in-process R&D - On **April 10, 2024**, Ginkgo acquired platform assets from AgBiome, Inc. for **$18.2 million**, paid with **407,240 shares of Class A common stock**, expanding its metagenomics database[40](index=40&type=chunk) - On **January 18, 2024**, Ginkgo completed the acquisition of substantially all of Zymergen's intellectual property assets for a total cash purchase price of **$6.2 million**[42](index=42&type=chunk) - Three other asset acquisitions during H1 2024 totaled **$19.8 million**, paid with **394,799 shares of Class A common stock**, and were expensed as acquired in-process research and development[45](index=45&type=chunk) [Note 3. Restructuring](index=14&type=section&id=Note%203.%20Restructuring) A Q2 2024 restructuring plan involves a workforce reduction of over 50% and facility consolidation, with estimated employee termination costs of **$27.0-$29.0 million** - A restructuring plan commenced in Q2 2024 includes a workforce reduction of more than **50%** and consolidation/subleasing of facilities[46](index=46&type=chunk) - Estimated costs for workforce reduction range from **$27.0 million to $29.0 million**, primarily in the Cell Engineering segment[47](index=47&type=chunk) Restructuring Costs Incurred (in thousands) | Cost Type | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Employee termination costs and other | $3,674 | $12,243 | $8,947 | $12,243 | | Impairment of right-of-use asset | — | $4,823 | — | $4,823 | | **Total restructuring** | **$3,674** | **$17,066** | **$8,947** | **$17,066** | - The accrued liability balance related to restructuring activities was **$2,568 thousand** as of June 30, 2025[50](index=50&type=chunk) [Note 4. Fair Value Measurements](index=15&type=section&id=Note%204.%20Fair%20Value%20Measurements) Total assets measured at fair value were **$467.5 million** as of June 30, 2025, with notes receivable and contingent consideration liabilities decreasing Fair Value Measurements (As of June 30, 2025, in thousands) | Category | Total | Level 1 | Level 2 | Level 3 | | :-------------------------------- | :------ | :------ | :------ | :------ | | **Assets:** | | | | | | Cash and cash equivalents | $187,762 | $171,888 | $15,835 | $— | | Marketable securities | $270,125 | $154,188 | $115,937 | $— | | Investments | $2,135 | $1,919 | $216 | $— | | Other non-current assets (Notes receivable) | $7,540 | $— | $— | $7,540 | | **Total Assets** | **$467,523** | **$327,9

[Executive Summary & Q2 2025 Highlights](index=1&type=section&id=1.%20Executive%20Summary%20%26%20Q2%202025%20Highlights) [Second Quarter 2025 Financial Performance](index=1&type=section&id=1.1.%20Second%20Quarter%202025%20Financial%20Performance) Ginkgo Bioworks reported a decrease in total revenue for Q2 2025 compared to the prior year, primarily due to a significant drop in Biosecurity revenue, while Cell Engineering revenue increased by 8%, and the company significantly reduced its GAAP net loss and improved Adjusted EBITDA | Metric | Q2 2025 (in millions) | Q2 2024 (in millions) | Change (YoY) | | :----------------------- | :-------------------- | :-------------------- | :----------- | | Total Revenue | $50 | $56 | -10.7% | | Cell Engineering Revenue | $39 | $36 | +8.3% | | Biosecurity Revenue | $10 | $20 | -50.0% | | GAAP Net Loss | $(60) | $(217) | Improved | | Adjusted EBITDA | $(28) | $(99) | Improved | - Cash, cash equivalents, and marketable securities stood at **$474 million** as of June 30, 2025[6](index=6&type=chunk) [Recent Business Highlights & Strategic Positioning](index=1&type=section&id=1.2.%20Recent%20Business%20Highlights%20%26%20Strategic%20Positioning) Ginkgo's platform is increasingly recognized as a critical engine for AI in biology, driving commercial traction through new government contracts and expanded biopharma service offerings, reinforcing its position in preclinical R&D and direct-to-scientist solutions - Ginkgo's Automation and Datapoints offerings are establishing themselves as critical tools in AI-powered bioengineering[6](index=6&type=chunk) - Pacific Northwest National Laboratory (PNNL) selected Ginkgo Automation to deliver a state-of-the-art automated anaerobic phenotyping platform[6](index=6&type=chunk) - Ginkgo launched a new in vitro ADME profiling Service, built on its proprietary RAC automation system, designed for scale, efficiency, and cost-effective assay quality[6](index=6&type=chunk) - Ginkgo launched its first direct-to-scientist product: an E. coli-based cell-free protein synthesis system optimized for high production and automation compatibility[6](index=6&type=chunk) [Full Year 2025 Outlook](index=1&type=section&id=1.3.%20Full%20Year%202025%20Outlook) Ginkgo achieved its annualized cost reduction target ahead of schedule and reaffirms its full-year 2025 revenue guidance, while continuing to work towards Adjusted EBITDA breakeven by the end of 2026 - Ginkgo achieved its target to reach **$250 million** in annualized cost reduction three months ahead of schedule through reductions in force and other cost-cutting measures[6](index=6&type=chunk) - Ginkgo reaffirms Total revenue guidance of **$167-$187 million** for 2025[6](index=6&type=chunk) - The company expects Cell Engineering revenue of **$117-$137 million** and Biosecurity revenue of at least **$40 million** in 2025[6](index=6&type=chunk) - Ginkgo continues to progress towards its objective to reach Adjusted EBITDA breakeven by the end of 2026[6](index=6&type=chunk) [Company Information & Disclosures](index=2&type=section&id=2.%20Company%20Information%20%26%20Disclosures) [Conference Call Details](index=2&type=section&id=2.1.%20Conference%20Call%20Details) Ginkgo Bioworks scheduled a videoconference for August 7, 2025, to discuss its second-quarter results, business updates, and outlook, including a Q&A session - Ginkgo will host a videoconference on Thursday, August 7, 2025, at 5:30 p.m. ET, with a webcast link available on its Investor Relations website[7](index=7&type=chunk)[8](index=8&type=chunk) [About Ginkgo Bioworks](index=2&type=section&id=2.2.%20About%20Ginkgo%20Bioworks) Ginkgo Bioworks is a platform company focused on making biology easier to engineer, offering R&D solutions, laboratory automation, data generation for AI models, and biosecurity infrastructure - Ginkgo Bioworks provides R&D Solutions (protein engineering, nucleic acid design, cell-free systems), Ginkgo Automation (modular lab automation), Ginkgo Datapoints (large lab data sets for AI), and Ginkgo Biosecurity (infrastructure for biological threats)[10](index=10&type=chunk) [Forward-Looking Statements](index=2&type=section&id=2.3.%20Forward-Looking%20Statements) The report contains forward-looking statements regarding future plans, operations, and financial results, which are subject to various risks and uncertainties that could cause actual outcomes to differ materially - Forward-looking statements in the press release, presentation, and conference call are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially[11](index=11&type=chunk)[13](index=13&type=chunk) - Key risks include the ability to realize cost savings from site consolidation, volatility in securities prices, demand for synthetic biology products and biosecurity services, and outcomes of legal proceedings[13](index=13&type=chunk) [Use of Non-GAAP Financial Measures](index=3&type=section&id=2.4.%20Use%20of%20Non-GAAP%20Financial%20Measures) Ginkgo includes non-GAAP financial measures, such as Adjusted EBITDA, to offer investors additional tools for evaluating financial performance, emphasizing that these should be considered supplemental to, not isolated from, GAAP measures - Non-GAAP financial measures, including Adjusted EBITDA, are provided as an additional tool for investors but should not be considered in isolation or as an alternative to GAAP measures[14](index=14&type=chunk) [Investor & Media Contacts](index=3&type=section&id=2.5.%20Investor%20%26%20Media%20Contacts) Contact information is provided for investor relations and media inquiries - Investor inquiries can be directed to investors@ginkgobioworks.com, and media inquiries to press@ginkgobioworks.com[15](index=15&type=chunk) [Condensed Consolidated Financial Statements](index=4&type=section&id=3.%20Condensed%20Consolidated%20Financial%20Statements) [Condensed Consolidated Balance Sheets](index=4&type=section&id=3.1.%20Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows a decrease in total assets and stockholders' equity from December 31, 2024, to June 30, 2025, primarily driven by a reduction in cash and cash equivalents, partially offset by an increase in marketable securities | Metric (in thousands) | As of June 30, 2025 | As of December 31, 2024 | | :-------------------------- | :------------------ | :---------------------- | | Total Assets | $1,231,009 | $1,377,449 | | Total Liabilities | $618,057 | $661,391 | | Total Stockholders' Equity | $612,952 | $716,058 | | Cash and cash equivalents | $203,566 | $561,572 | | Marketable securities | $270,125 | — | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=7&type=section&id=3.2.%20Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the three and six months ended June 30, 2025, Ginkgo reported a significant reduction in net loss and loss from operations compared to the prior year periods, despite a slight decrease in total revenue for the quarter, largely due to reduced operating expenses, particularly in research and development and general and administrative costs | Metric (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Total revenue | $49,604 | $56,206 | $97,922 | $94,150 | | Loss from operations | $(65,541) | $(222,945) | $(154,509) | $(400,947) | | Net loss | $(60,300) | $(217,181) | $(151,257) | $(383,092) | | Basic Net loss per share | $(1.10) | $(4.23) | $(2.77) | $(7.55) | | Diluted Net loss per share | $(1.10) | $(4.23) | $(2.77) | $(7.56) | - Research and development expenses decreased significantly from **$134.221 million** in Q2 2024 to **$53.370 million** in Q2 2025[19](index=19&type=chunk) - General and administrative expenses also saw a notable reduction from **$66.285 million** in Q2 2024 to **$43.279 million** in Q2 2025[19](index=19&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=3.3.%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, net cash used in operating activities decreased, but net cash used in investing activities increased substantially due to significant purchases of marketable debt securities, resulting in a larger overall net decrease in cash and cash equivalents compared to the prior year | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | | Net cash used in operating activities | $(91,775) | $(173,649) | | Net cash used in investing activities | $(262,572) | $(38,951) | | Net cash used in financing activities | $(305) | $(1,071) | | Net decrease in cash, cash equivalents and restricted cash | $(354,392) | $(213,844) | | Cash, cash equivalents and restricted cash, end of period | $251,351 | $775,740 | - Purchases of marketable debt securities totaled **$320.132 million** for the six months ended June 30, 2025, compared to none in the prior year period[22](index=22&type=chunk) [Segment Information](index=12&type=section&id=4.%20Segment%20Information) Ginkgo's segment reporting shows that Cell Engineering revenue increased while Biosecurity revenue decreased for both the three and six months ended June 30, 2025, with both segments continuing to report operating losses, though Cell Engineering significantly reduced its loss year-over-year | Segment (in thousands) | Q2 2025 Revenue | Q2 2024 Revenue | 6M 2025 Revenue | 6M 2024 Revenue | | :--------------------- | :-------------- | :-------------- | :-------------- | :-------------- | | Cell Engineering | $39,134 | $36,205 | $77,364 | $64,094 | | Biosecurity | $10,470 | $20,001 | $20,558 | $30,056 | | **Operating Loss** | | | | | | Cell Engineering | $(9,937) | $(83,024) | $(41,525) | $(175,277) | | Biosecurity | $(4,815) | $(3,443) | $(9,999) | $(14,661) | - Cell Engineering operating loss significantly improved from **$(83.024) million** in Q2 2024 to **$(9.937) million** in Q2 2025[25](index=25&type=chunk) - Restructuring charges for Q2 2025 were **$3.674 million**, a substantial decrease from **$17.066 million** in Q2 2024, primarily consisting of employee termination costs[25](index=25&type=chunk)[31](index=31&type=chunk) [Selected Non-GAAP Financial Measures Reconciliation](index=14&type=section&id=5.%20Selected%20Non-GAAP%20Financial%20Measures%20Reconciliation) The reconciliation of GAAP net loss to Adjusted EBITDA demonstrates a significant improvement in Adjusted EBITDA for both the three and six months ended June 30, 2025, compared to the prior year periods, reflecting the impact of cost reduction efforts and other adjustments | Metric (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net loss | $(60,300) | $(217,181) | $(151,257) | $(383,092) | | Adjusted EBITDA | $(28,061) | $(99,199) | $(75,512) | $(216,200) | - Adjusted EBITDA improved by **$71.138 million** for the three months ended June 30, 2025, and by **$140.688 million** for the six months ended June 30, 2025, compared to the respective prior year periods[30](index=30&type=chunk) - Adjustments to Net Loss for Adjusted EBITDA include significant reductions in stock-based compensation and the absence of goodwill impairment charges in 2025, which were present in 2024[30](index=30&type=chunk)

Core Insights - Ginkgo Bioworks has achieved its $250 million annualized cost-reduction goal three months ahead of schedule, driven by financial discipline and restructuring efforts [2][9][24] - The company reported a total revenue of $50 million for Q2 2025, a decrease from $56 million in the same period last year, with notable growth in Cell Engineering revenue [9][15] - Ginkgo's strategic positioning includes expanding its service offerings in response to increasing demand in the biopharma industry and securing major government contracts [2][9] Financial Performance - Total revenue for Q2 2025 was $50 million, down from $56 million in Q2 2024 [9] - Cell Engineering revenue increased to $39 million, up 8% from $36 million in the prior year [9] - Biosecurity revenue decreased to $10 million, down from $20 million in the comparable prior year period [9] - GAAP net loss for Q2 2025 was $(60) million, significantly improved from $(217) million in Q2 2024 [9] - Adjusted EBITDA improved to $(28) million from $(99) million in the prior year [9] Business Highlights - Ginkgo's Automation and Datapoints offerings are becoming essential tools in AI-powered bioengineering [9] - The company launched a new in vitro ADME profiling service, enhancing its capabilities in preclinical R&D analytical services [9] - Ginkgo introduced its first direct-to-scientist product, a cell-free protein synthesis system optimized for high production [9] Outlook - Ginkgo reaffirms its total revenue guidance for 2025 to be between $167 million and $187 million [9] - The company expects Cell Engineering revenue to be between $117 million and $137 million in 2025 [9] - Biosecurity revenue is projected to be at least $40 million in 2025 [9]

Company Overview - Ginkgo Bioworks is focused on building a leading platform for cell programming and biosecurity [1] - The company offers customizable R&D packages, including protein engineering and nucleic acid design, to accelerate innovation in therapeutics, diagnostics, and manufacturing [3] - Ginkgo Automation provides modular laboratory automation solutions to enhance scientific productivity [3] - Ginkgo Biosecurity is developing next-generation infrastructure and technologies to address biological threats [3] Upcoming Events - Ginkgo Bioworks will host a presentation and Q&A session on August 7, 2025, to review its business performance for Q2 2025 [1] - The session will begin at 5:30 p.m. ET and will be available via webcast on the company's investor relations website [2] - Questions can be submitted in advance through social media or email [2]

Core Insights - Ginkgo Bioworks has been selected by the Environmental Molecular Sciences Laboratory (EMSL) to deliver an automated anaerobic phenotyping platform, marking a significant advancement in biological research and bioeconomy leadership [1][6] - The contract, valued at $4.66 million, involves constructing a fully integrated workcell with 18 devices within a modular anaerobic chamber, designed to enhance laboratory efficiency and data quality [3][4] - Ginkgo Automation's Reconfigurable Automation Cart (RAC) technology will enable remote operation of complex workflows, streamlining research processes and accelerating discovery in microbial engineering and biodesign [4][5] Company Overview - Ginkgo Bioworks focuses on making biology easier to engineer, providing customizable R&D solutions across therapeutics, diagnostics, and manufacturing [7] - The company offers modular laboratory automation systems that allow scientists to focus on planning and analyzing experiments rather than manual tasks [7] - Ginkgo's automation technology has been deployed in various labs, resulting in increased throughput, repeatability, and reduced cycle times [5][6]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a decline of 6.31% in its stock price, closing at $13.96, while the S&P 500 gained 0.4% [1] - Over the past month, the company's shares have increased by 55.05%, significantly outperforming the Medical sector's gain of 1.19% and the S&P 500's gain of 4.61% [1] Earnings Projections - The upcoming earnings disclosure for Ginkgo Bioworks is projected to show an earnings per share (EPS) of -$1.44, which reflects a 55% increase from the same quarter last year [2] - Revenue is estimated to be $43 million, indicating a 23.5% decrease compared to the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, Zacks Consensus Estimates predict an EPS of -$5.56 and revenue of $180 million, representing changes of +46.33% and -20.72% from the previous year, respectively [3] - Recent changes to analyst estimates for Ginkgo Bioworks are important as they indicate the evolving nature of near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Position - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a proven track record of outperformance, with 1 stocks returning an average of +25% annually since 1988 [5] - Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate remaining unchanged over the last 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 95, placing it in the top 39% of over 250 industries [6] - The strength of individual industry groups is measured by the Zacks Industry Rank, which is based on the average Zacks Rank of individual stocks, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Viewpoint - Ginkgo Bioworks has launched a cost-effective, high-throughput ADME profiling service aimed at accelerating small molecule drug discovery, with a focus on providing model-ready datasets and competitive pricing compared to international vendors [1][2][3] Company Overview - Ginkgo Bioworks is positioned as a leading platform for cell programming and biosecurity, offering integrated laboratory automation and large lab datasets to support AI model development [4] New Service Features - The new ADME profiling service is designed to enhance the drug development pipeline for small molecules, providing early access to rich ADME data that empowers researchers to prioritize candidates and train predictive models efficiently [2][6] - Key features include automated workflows, cost-effective pricing with a price match guarantee against international vendors, and rapid turnaround times to align with modern discovery cycles [6][3] Leadership Statement - Jason Kelly, co-founder and CEO of Ginkgo Bioworks, expressed confidence that the new ADME service will be transformative for drug discovery, emphasizing the company's ability to offer competitive pricing and quality through automation and scale [3]

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.60, reflecting a +1.8% change from the previous day's closing price, outperforming the S&P 500's gain of 0.32% [1] - Over the past month, the company's shares have appreciated by 10.29%, contrasting with the Medical sector's decline of 3.4% and the S&P 500's increase of 4.51% [1] Upcoming Financial Results - Ginkgo Bioworks is expected to report earnings of -$1.44 per share, indicating a year-over-year growth of 55%, while revenue is projected to be $43 million, representing a 23.5% decline compared to the same quarter last year [2] - For the annual period, the Zacks Consensus Estimates predict earnings of -$5.56 per share and revenue of $180 million, reflecting changes of +46.33% and -20.72% respectively from the previous year [3] Analyst Estimates and Stock Performance - Changes in analyst estimates for Ginkgo Bioworks are crucial as they indicate shifting business trends, with positive revisions suggesting analyst optimism about profitability [3] - The Zacks Rank system, which evaluates these estimate changes, currently assigns Ginkgo Bioworks a rank of 2 (Buy), indicating a favorable outlook [5] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [6]